A Phase 1 interventional study of Olanzapine Extended Release and Olanzapine Immediate Release in Schizophrenia, Schizoaffective Disorder, sponsored by Teva Branded Pharmaceutical Products R&D LLC. Completed at 5 sites in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-01-26.
Sponsored by Teva Branded Pharmaceutical Products R&D LLC (part of Teva Pharmaceutical Industries, Ltd.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 97 studies testing olanzapine in Schizophrenia — 2 open to participants now, 3 under way, 1 of them phase 3. Olanzapine · Schizophrenia.
Among the 97 studies testing olanzapine in Schizophrenia, this one is the 53rd largest by enrollment of the 94 interventional ones that give a count, is the only one that started in 2024, is one of 7 in phase 1, and was the 96th registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →2 of the 97 studies testing olanzapine in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:
Minerva Neurosciences · Sites in United States
Ages 18–55
Centre for Addiction and Mental Health · Sites in Canada
Ages 18+
By country, each count listing its studies:
Olanzapine: first FDA approval 1996 (ZYPREXA), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
97 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 8 · Phase 3 25 · Phase 4 46
First in 1997; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 106 is above the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 114 across the 94 interventional studies. Of the 86 that completed or were terminated, 25 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 97 have an industry lead sponsor. The 10 most frequent:
This study is registered under Teva Branded Pharmaceutical Products R&D LLC, one of the names counted as Teva Pharmaceutical Industries, Ltd.. Under that name alone:
Teva Branded Pharmaceutical Products R&D LLC is the lead sponsor of 24 studies on the registry; 7 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 8 (73%) have results posted.
Teva Pharmaceutical Industries, Ltd. has 9 studies filed under Schizophrenia — fewer than ten, so there is no comparison to draw.
2 of the studies testing olanzapine in Schizophrenia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03781115University of ArizonaProposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia | 2027-02-10 |
| NCT04478838Centre for Addiction and Mental Health"Extended" (Alternate Day) Antipsychotic Dosing | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 97 studies testing olanzapine in Schizophrenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to characterize the pharmacokinetics of 3 formulations of olanzapine.
A secondary objective is to evaluate the safety and tolerability of 3 formulations of olanzapine.
Another secondary objective is to characterize the pharmacokinetics of ZYPREXA.
The planned duration of the study for each participant is 19 weeks.
All participants received immediate-release ZYPREXA and then were randomized into 1 of 3 extended-release olanzapine formulations.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
NOTE- Additional criteria apply, please contact the investigator for more information
Exclusion Criteria:
NOTE- Additional criteria apply, please contact the investigator for more information
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single-dose injection
Drug: Olanzapine Extended Release
Single-dose injection
Drug: Olanzapine Extended Release
Single-dose injection
Drug: Olanzapine Extended Release
Single-dose injection
Drug: Olanzapine Immediate Release
Powder and vehicle for injectable suspension
IntraMuscular Injection
Also known as: ZYPREXA
Maximum Observed Plasma Concentration (Cmax) of Olanzapine (Extended-release Formulation)
Time frame: Randomization Day 1 to 84 days after randomization
Area Under the Plasma Concentration-time Curve From Study Drug Administration to the Last Measurable Concentration (AUC0-t) of Olanzapine (Extended-release Formulation)
Time frame: Randomization Day 1 to 84 days after randomization
Area Under the Plasma Concentration-time Curve Extrapolated to Infinity (AUC0-inf) of Olanzapine (Extended-release Formulation)
Time frame: Randomization Day 1 to 84 days after randomization
Number of Participants With at Least 1 Treatment-emergent Adverse Event (TEAE) Over the 28-day Period Following Administration of 1 of the SC Olanzapine Formulations
An adverse event (AE) was defined as any untoward medical occurrence in a participant who received the study drug without regard to possibility of causal relationship. A TEAE was defined as an AE that occurred after the first dose of study drug administration through the end of trial. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in the Reported AE section.
Time frame: Randomization Day 1 through Randomization Day 29
Number of Participants With at Least 1 Serious Adverse Event (SAE) Over the 28-day Period Following Administration of 1 of the SC Olanzapine Formulations
The SAEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in the Reported AE section.
Time frame: Randomization Day 1 through Randomization Day 29
Cmax of ZYPREXA (Immediate-release Formulation)
Time frame: Up to 24 hours after administration of ZYPREXA (Day 4)
AUC0-t of ZYPREXA (Immediate-release Formulation)
Time frame: Predose (Day 4) up to 216 hours after administration of ZYPREXA (Day 13)
Apparent Plasma Terminal Elimination Rate Constant (λz) of ZYPREXA (Immediate-release Formulation)
Time frame: Predose (Day 4) up to 216 hours after administration of ZYPREXA (Day 13)
| Milestone | ZYPREXA | Cohort 1: Olanzapine (Fast-D) | Cohort 2: Olanzapine (To-be-marketed) | Cohort 3: Olanzapine (Slow-C) |
|---|---|---|---|---|
| Started | 106 | 0 | 0 | 0 |
| Received at least 1 dose of study drug | 98 | 0 | 0 | 0 |
| Completed | 91 | 0 | 0 | 0 |
| Not completed | 15 | 0 | 0 | 0 |
| Withdrew: Enrolled but not treated | 8 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 3 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 2 | 0 | 0 | 0 |
| Withdrew: Other than specified | 2 | 0 | 0 | 0 |
| Milestone | ZYPREXA | Cohort 1: Olanzapine (Fast-D) | Cohort 2: Olanzapine (To-be-marketed) | Cohort 3: Olanzapine (Slow-C) |
|---|---|---|---|---|
| Started | 0 | 29 | 31 | 31 |
| Received at least 1 dose of study drug | 0 | 29 | 31 | 31 |
| Completed | 0 | 28 | 29 | 31 |
| Not completed | 0 | 1 | 2 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 2 | 0 |
| Withdrew: Other than specified | 0 | 1 | 0 | 0 |
| Milestone | ZYPREXA | Cohort 1: Olanzapine (Fast-D) | Cohort 2: Olanzapine (To-be-marketed) | Cohort 3: Olanzapine (Slow-C) |
|---|---|---|---|---|
| Started | 0 | 28 | 29 | 31 |
| Completed | 0 | 27 | 27 | 30 |
| Not completed | 0 | 1 | 2 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 |
| Withdrew: Other than specified | 0 | 0 | 0 | 1 |
| nanograms (ng)/milliliter (mL) | Cohort 1: Olanzapine (Fast-D) | Cohort 2: Olanzapine (To-be-marketed) | Cohort 3: Olanzapine (Slow-C) |
|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Olanzapine (Extended-release Formulation) | 39.26 ± 45.10 | 35.62 ± 67.55 | 29.68 ± 50.13 |
| hours*ng/mL | Cohort 1: Olanzapine (Fast-D) | Cohort 2: Olanzapine (To-be-marketed) | Cohort 3: Olanzapine (Slow-C) |
|---|---|---|---|
| Area Under the Plasma Concentration-time Curve From Study Drug Administration to the Last Measurable Concentration (AUC0-t) of Olanzapine (Extended-release Formulation) | 20994.08 ± 33.77 | 20185.90 ± 47.35 | 18461.94 ± 35.44 |
| hours*ng/mL | Cohort 1: Olanzapine (Fast-D) | Cohort 2: Olanzapine (To-be-marketed) | Cohort 3: Olanzapine (Slow-C) |
|---|---|---|---|
| Area Under the Plasma Concentration-time Curve Extrapolated to Infinity (AUC0-inf) of Olanzapine (Extended-release Formulation) | 21703.07 ± 35.06 | 22146.09 ± 42.77 | 19011.66 ± 37.21 |
An adverse event (AE) was defined as any untoward medical occurrence in a participant who received the study drug without regard to possibility of causal relationship. A TEAE was defined as an AE that occurred after the first dose of study drug administration through the end of trial. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in the Reported AE section.
| Participants | Cohort 1: Olanzapine (Fast-D) | Cohort 2: Olanzapine (To-be-marketed) | Cohort 3: Olanzapine (Slow-C) |
|---|---|---|---|
| Number of Participants With at Least 1 Treatment-emergent Adverse Event (TEAE) Over the 28-day Period Following Administration of 1 of the SC Olanzapine Formulations | 9 | 12 | 9 |
The SAEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in the Reported AE section.
| Participants | Cohort 1: Olanzapine (Fast-D) | Cohort 2: Olanzapine (To-be-marketed) | Cohort 3: Olanzapine (Slow-C) |
|---|---|---|---|
| Number of Participants With at Least 1 Serious Adverse Event (SAE) Over the 28-day Period Following Administration of 1 of the SC Olanzapine Formulations | 0 | 1 | 0 |
| ng/mL | ZYPREXA |
|---|---|
| Cmax of ZYPREXA (Immediate-release Formulation) | 11.09 ± 82.89 |
| hours*ng/mL | ZYPREXA |
|---|---|
| AUC0-t of ZYPREXA (Immediate-release Formulation) | 264.22 ± 48.14 |
| 1/hour | ZYPREXA |
|---|---|
| Apparent Plasma Terminal Elimination Rate Constant (λz) of ZYPREXA (Immediate-release Formulation) | 0.0159 ± 0.00381 |
Collected over Day 1 up to Day 84. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ZYPREXA | 0/106 (0%) | 0/98 (0%) | 18/98 (18.4%) |
| Cohort 1: Olanzapine (Fast-D) | 0/29 (0%) | 0/29 (0%) | 8/29 (27.6%) |
| Cohort 2: Olanzapine (To-be-marketed) | 0/31 (0%) | 1/31 (3.2%) | 11/31 (35.5%) |
| Cohort 3: Olanzapine (Slow-C) | 0/31 (0%) | 0/31 (0%) | 6/31 (19.4%) |
| Event | ZYPREXA | Cohort 1: Olanzapine (Fast-D) | Cohort 2: Olanzapine (To-be-marketed) | Cohort 3: Olanzapine (Slow-C) |
|---|---|---|---|---|
| Suicidal ideationPsychiatric disorders | 0/98 | 0/29 | 1/31 | 0/31 |
| Event | ZYPREXA | Cohort 1: Olanzapine (Fast-D) | Cohort 2: Olanzapine (To-be-marketed) | Cohort 3: Olanzapine (Slow-C) |
|---|---|---|---|---|
| Injection site painGeneral disorders | 0/98 | 2/29 | 3/31 | 0/31 |
| SomnolenceNervous system disorders | 5/98 | 1/29 | 3/31 | 2/31 |
| Injection site irritationGeneral disorders | 0/98 | 2/29 | 0/31 | 1/31 |
| Psychotic disorderPsychiatric disorders | 0/98 | 2/29 | 1/31 | 1/31 |
| Urinary tract infectionInfections and infestations | 5/98 | 0/29 | 2/31 | 0/31 |
| Alanine aminotransferase increasedInvestigations | 1/98 | 0/29 | 1/31 | 2/31 |
| Aspartate aminotransferase increasedInvestigations | 1/98 | 0/29 | 1/31 | 2/31 |
| Blood creatine phosphokinase increasedInvestigations | 1/98 | 1/29 | 2/31 | 0/31 |
| HeadacheNervous system disorders | 6/98 | 0/29 | 1/31 | 0/31 |
The Enrolled Analysis Set included all participants who signed an informed consent form (ICF) and were enrolled in the trial.
| Age, Continuous(years) | ZYPREXA Only (Not Randomized) | Cohort 1: Olanzapine (Fast-D) | Cohort 2: Olanzapine (To-be-marketed) | Cohort 3: Olanzapine (Slow-C) | Total |
|---|---|---|---|---|---|
| Mean | 37.9 ± 11.95 | 45.7 ± 11.88 | 43.3 ± 11.39 | 42.1 ± 11.48 | 42.8 ± 11.72 |
| Sex: Female, Male(Participants) | ZYPREXA Only (Not Randomized) | Cohort 1: Olanzapine (Fast-D) | Cohort 2: Olanzapine (To-be-marketed) | Cohort 3: Olanzapine (Slow-C) | Total |
|---|---|---|---|---|---|
| Female | 2 | 11 | 6 | 10 | 29 |
| Male | 13 | 18 | 25 | 21 | 77 |
| Ethnicity (NIH/OMB)(Participants) | ZYPREXA Only (Not Randomized) | Cohort 1: Olanzapine (Fast-D) | Cohort 2: Olanzapine (To-be-marketed) | Cohort 3: Olanzapine (Slow-C) | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 3 | 7 | 11 | 8 | 29 |
| Not Hispanic or Latino | 12 | 22 | 20 | 23 | 77 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | ZYPREXA Only (Not Randomized) | Cohort 1: Olanzapine (Fast-D) | Cohort 2: Olanzapine (To-be-marketed) | Cohort 3: Olanzapine (Slow-C) | Total |
|---|---|---|---|---|---|
| Race — White | 6 | 7 | 14 | 10 | 37 |
| Race — Black or African American | 9 | 22 | 14 | 19 | 64 |
| Race — Asian | 0 | 0 | 0 | 2 | 2 |
| Race — Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 0 | 1 |
| Race — Other | 0 | 0 | 2 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the study protocol and the statistical analysis plan. Requests will be assessed for scientific merit, product approval status, and conflicts of interest. If the request is approved, patient level data will be de-identified and study documents will be redacted to protect the privacy of trial participants and to protect commercially confidential information. Please visit USMedInfo@tevapharm.com to make your request.
Ran from Mar 2024 to primary completion in Jan 2025, 9 months.
Results were first posted in Jan 2026, 1 year after primary completion.
Of 108 industry-sponsored phase 1 interventional studies under Schizophrenia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 9 months is close to that.
Counting every sponsor, half of 133 studies reached it within 12 months; a quarter within 5 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olanzapine
Teva Branded Pharmaceutical Products R&D LLC →